Is OCGN or KLRS more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Kalaris Therapeutics N/A -72.78% -43.49%

Does the media prefer OCGN or KLRS?

In the previous week, Ocugen and Ocugen both had 3 articles in the media. Ocugen's average media sentiment score of 0.96 beat Kalaris Therapeutics' score of 0.47 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, KLRS or KYTX?

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A

Is KLRS or KYTX more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media favor KLRS or KYTX?

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 3 articles in the media. Kyverna Therapeutics' average media sentiment score of 1.61 beat Kalaris Therapeutics' score of 0.47 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to KLRS or OVID?

In the previous week, Ovid Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Ovid Therapeutics and 3 mentions for Kalaris Therapeutics. Ovid Therapeutics' average media sentiment score of 1.60 beat Kalaris Therapeutics' score of 0.47 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor KLRS or PRTA?

In the previous week, Prothena had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Prothena and 3 mentions for Kalaris Therapeutics. Prothena's average media sentiment score of 1.50 beat Kalaris Therapeutics' score of 0.47 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CABA or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A

Is CABA or KLRS more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Kalaris Therapeutics N/A -72.78% -43.49%

Does the media refer more to CABA or KLRS?

In the previous week, Cabaletta Bio and Cabaletta Bio both had 3 articles in the media. Cabaletta Bio's average media sentiment score of 0.97 beat Kalaris Therapeutics' score of 0.47 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kalaris Therapeutics (KLRS) Competitors

$3.73 -0.19 (-4.85%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.76 +0.03 (+0.83%)

As of 07/24/2026 07:34 PM Eastern

Compare

KLRS vs. OCGN, KYTX, OVID, PRTA, and CABA

Should you buy Kalaris Therapeutics stock or one of its competitors? MarketBeat compares Kalaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kalaris Therapeutics include Ocugen (OCGN), Kyverna Therapeutics (KYTX), Ovid Therapeutics (OVID), Prothena (PRTA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.

How does Kalaris Therapeutics compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Ocugen and Ocugen both had 3 articles in the media. Ocugen's average media sentiment score of 0.96 beat Kalaris Therapeutics' score of 0.47 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 685.12%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 402.68%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Kalaris Therapeutics' return on equity of -72.78% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ocugen has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Kalaris Therapeutics has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	91.74	-$67.85M	-$0.24	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Summary

Kalaris Therapeutics beats Ocugen on 9 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Kyverna Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Kalaris Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 402.68%. Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 304.86%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kalaris Therapeutics' return on equity of -72.78% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Kalaris Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 3 articles in the media. Kyverna Therapeutics' average media sentiment score of 1.61 beat Kalaris Therapeutics' score of 0.47 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Kalaris Therapeutics beats Kyverna Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Ovid Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Kalaris Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Ovid Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Ovid Therapeutics	$7.25M	59.98	-$17.41M	-$0.29	N/A

In the previous week, Ovid Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Ovid Therapeutics and 3 mentions for Kalaris Therapeutics. Ovid Therapeutics' average media sentiment score of 1.60 beat Kalaris Therapeutics' score of 0.47 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kalaris Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Kalaris Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 402.68%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 119.96%. Given Kalaris Therapeutics' higher possible upside, equities analysts plainly believe Kalaris Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ovid Therapeutics beats Kalaris Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Prothena?

Kalaris Therapeutics (NASDAQ:KLRS) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Prothena had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Prothena and 3 mentions for Kalaris Therapeutics. Prothena's average media sentiment score of 1.50 beat Kalaris Therapeutics' score of 0.47 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Prothena has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kalaris Therapeutics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Prothena	$9.68M	47.32	-$244.09M	-$2.82	N/A

Kalaris Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Prothena	-260.92%	-43.44%	-36.87%

Kalaris Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 402.68%. Prothena has a consensus target price of $23.75, suggesting a potential upside of 171.43%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kalaris Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Kalaris Therapeutics beats Prothena on 9 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Kalaris Therapeutics' return on equity of -72.78% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Kalaris Therapeutics	N/A	-72.78%	-43.49%

In the previous week, Cabaletta Bio and Cabaletta Bio both had 3 articles in the media. Cabaletta Bio's average media sentiment score of 0.97 beat Kalaris Therapeutics' score of 0.47 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cabaletta Bio has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Cabaletta Bio currently has a consensus price target of $15.50, indicating a potential upside of 476.21%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 402.68%. Given Cabaletta Bio's higher probable upside, equities analysts clearly believe Cabaletta Bio is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kalaris Therapeutics beats Cabaletta Bio on 8 of the 13 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$93.27M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.73	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.89	7.88	10.28	6.07
Net Income	-$43.44M	$23.86M	$3.60B	$331.99M
7 Day Performance	-14.84%	-3.82%	-1.27%	-0.63%
1 Month Performance	-13.26%	-2.61%	-0.37%	-2.00%
1 Year Performance	35.14%	32.79%	18.30%	13.62%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	4.0343 of 5 stars	$3.73 -4.8%	$18.75 +402.7%	+31.3%	$93.27M	N/A	N/A	110
OCGN Ocugen	2.4191 of 5 stars	$1.36 -1.1%	$9.50 +601.1%	+8.0%	$458.70M	$4.41M	N/A	80	Upcoming Earnings
KYTX Kyverna Therapeutics	2.6501 of 5 stars	$7.51 +0.9%	$30.00 +299.7%	+74.8%	$456.47M	N/A	N/A	96	Positive News
OVID Ovid Therapeutics	2.3054 of 5 stars	$2.45 -0.2%	$5.13 +109.6%	+236.2%	$456.34M	$7.25M	N/A	60	News Coverage Positive News Analyst Forecast Gap Up
PRTA Prothena	3.9993 of 5 stars	$8.70 +2.7%	$23.75 +173.1%	+30.6%	$455.34M	$9.68M	N/A	130	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. OCGN, KYTX, OVID, PRTA, and CABA

How does Kalaris Therapeutics compare to Ocugen?

Summary

How does Kalaris Therapeutics compare to Kyverna Therapeutics?

Summary

How does Kalaris Therapeutics compare to Ovid Therapeutics?

Summary

How does Kalaris Therapeutics compare to Prothena?

Summary

How does Kalaris Therapeutics compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. OCGN, KYTX, OVID, PRTA, and CABA

How does Kalaris Therapeutics compare to Ocugen?

Does the media prefer OCGN or KLRS?

Do analysts recommend OCGN or KLRS?

Is OCGN or KLRS more profitable?

Do insiders and institutionals hold more shares of OCGN or KLRS?

Which has more risk & volatility, OCGN or KLRS?

Which has stronger earnings and valuation, OCGN or KLRS?

Summary

How does Kalaris Therapeutics compare to Kyverna Therapeutics?

Do analysts prefer KLRS or KYTX?

Do insiders and institutionals hold more shares of KLRS or KYTX?

Is KLRS or KYTX more profitable?

Which has more volatility and risk, KLRS or KYTX?

Which has higher valuation and earnings, KLRS or KYTX?

Does the media favor KLRS or KYTX?

Summary

How does Kalaris Therapeutics compare to Ovid Therapeutics?

Is KLRS or OVID more profitable?

Which has preferable valuation and earnings, KLRS or OVID?

Does the media refer more to KLRS or OVID?

Which has more volatility & risk, KLRS or OVID?

Do analysts prefer KLRS or OVID?

Do insiders & institutionals believe in KLRS or OVID?

Summary

How does Kalaris Therapeutics compare to Prothena?

Does the media favor KLRS or PRTA?

Which has more risk and volatility, KLRS or PRTA?

Do institutionals and insiders believe in KLRS or PRTA?

Which has higher earnings and valuation, KLRS or PRTA?

Is KLRS or PRTA more profitable?

Do analysts prefer KLRS or PRTA?

Summary

How does Kalaris Therapeutics compare to Cabaletta Bio?

Which has preferable earnings & valuation, CABA or KLRS?

Is CABA or KLRS more profitable?

Does the media refer more to CABA or KLRS?

Do institutionals and insiders believe in CABA or KLRS?

Which has more risk & volatility, CABA or KLRS?

Do analysts recommend CABA or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools